China's GHW International interim revenue rises on segment growth

GHW International

25/08/2026 13:31

Overview
China chemical and pharmaceutical maker's interim revenue grew 20% yr/yr
Net profit for the period rose over 300%, driven by higher gross profit

Outlook
Company did not provide specific financial guidance for future quarters or the full year

Result Drivers
SEGMENT GROWTH - Revenue increased in Methylamine Industry Series, Goldenhighway New Materials, and Advanced Materials Intermediates Series, driven by higher sales volumes, expanded market share, and new trading products
PRICE AND VOLUME EFFECTS - Higher average selling prices and increased sales volumes of choline chloride and betaine, as well as polymeric MDI, supported gross profit growth
FULL PRODUCTION RESUMPTION - Advanced Materials Intermediates Series benefited from the resumption of full production capacity and new trading products such as isooctanol

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 2.23 bln
 
H1 Net Income Attributable
 
RMB 29.40 mln
 

Reuters Recommended Reads
Aug 25 - China's Sinofert H1 revenue rises 10.6% on policy support
Aug 24 - China's Asymchem H1 revenue rises on strength in emerging businesses
Aug 24 - Sinopharm interim revenue edges down on softness in pharmaceutical distribution business

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/fingerpost/HKSW/2026-08-25/973560ba-15e1-4813-aa7c-3735c0be6a12.file
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)